DCTH Stock Overview
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.
+ 1 more risk
Delcath Systems, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.10|
|52 Week High||US$11.95|
|52 Week Low||US$2.98|
|1 Month Change||-25.84%|
|3 Month Change||-22.31%|
|1 Year Change||-69.37%|
|3 Year Change||-95.96%|
|5 Year Change||-100.00%|
|Change since IPO||-100.00%|
Recent News & Updates
Delcath Systems Q2 2022 Earnings Preview
Delcath Systems (NASDAQ:DCTH) is scheduled to announce Q2 earnings results on Monday, August 8th, before market open. The consensus EPS Estimate is -$1.01 (-5.2% Y/Y) and the consensus Revenue Estimate is $0.42M (-22.2% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions and 2 downward. Revenue estimates have seen 1 upward revision and 1 downward.
|DCTH||US Medical Equipment||US Market|
Return vs Industry: DCTH underperformed the US Medical Equipment industry which returned -31.4% over the past year.
Return vs Market: DCTH underperformed the US Market which returned -22.1% over the past year.
|DCTH Average Weekly Movement||7.2%|
|Medical Equipment Industry Average Movement||8.6%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: DCTH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: DCTH's weekly volatility (7%) has been stable over the past year.
About the Company
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma.
Delcath Systems, Inc. Fundamentals Summary
|DCTH fundamental statistics|
Is DCTH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DCTH income statement (TTM)|
|Cost of Revenue||US$571.00k|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-3.53|
|Net Profit Margin||-797.16%|
How did DCTH perform over the long term?See historical performance and comparison